Data as of Nov 4, 2026.
KIQQ vs PCOV: Dividend Yield & Total Return
KIQQ and PCOV both write options for income.
askIQ about this page
askIQ about KIQQ and PCOV
Net assets: $2.4m on Nov 4, 2026 for KraneShares InspereX Nasdaq Dynamic Buffered High Income Index ETF, and $10m on Nov 2, 2026 for Principal Equity Premium Income ETF.
10.4 pts behind QQQ
KIQQ since launch: paid 6.9%, price −6.0%, total +0.9%, QQQ +11.3%, −10.4 pts. Data to Nov 4, 2026.
QQQ
+11.3%
KIQQ
+0.9%
10.4 pts behind QQQ
Total return, distributions reinvested
10.4 pts behind QQQ
KIQQ since launch: paid 6.9%, price −6.0%, total +0.9%, QQQ +11.3%, −10.4 pts. Data to Nov 4, 2026.
QQQ
+11.3%
KIQQ
+0.9%
10.4 pts behind QQQ
6.9% of it arrived as cash. Total return, distributions reinvested. KIQQ since launch: paid 6.9%, price −6.0%, total +0.9%, QQQ +11.3%, −10.4 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
Total return, distributions reinvested
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
1.9% of it arrived as cash. Both charts share one scale, with zero at the line. PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
PCOV costs 0.45 points a year less; PCOV is 4.3 times larger.
Points (pts) are percentage points.
| Measure | KIQQ | PCOV |
|---|---|---|
| Paid and earned | ||
| Price change | fell 6.0% (since Jan 7, 2026) | fell 2.0% (since Aug 19, 2026) |
| Return of capital, issuer estimate | 99% of the Sep 30, 2026 payment | |
| Against its benchmark | ||
| Benchmark | Nasdaq-100, measured through QQQ | not published |
| Cost and size | ||
| Expense ratio | 0.79% | 0.34% |
| Net assets, as of Nov 3, 2026 | $2.3m | $10m |
| Holdings | ||
| Holdings in common | not published | |
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | KIQQ | PCOV | KIQQ | PCOV | KIQQ | PCOV |
| 3 months | −3.7% | – | 1.7% | – | −0.2 pts | – |
| 6 months | −4.4% | – | 3.7% | – | −4.0 pts | – |
| Since launchNot the same days: KIQQ Jan 2026 · PCOV Aug 2026 | +0.9% | −0.1% | 6.9% | 1.9% | −10.4 pts | not measured |
– means no data for this window. Open this comparison in the app →
KIQQ
Over the period from its first trade on Jan 7, 2026 to Nov 4, 2026, KIQQ paid 6.9% of its starting value in cash distributions while its price fell 6.0%. With every distribution reinvested, the fund returned +0.9%. Nasdaq-100 (QQQ) returned +11.3% over the same days, so a holder was behind by 10.4 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 7.5%, paid monthly. KraneShares estimates that 99% of the distribution paid Sep 30, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
PCOV
Over the period from its first trade on Aug 19, 2026 to Nov 4, 2026, PCOV paid 1.9% of its starting value in cash distributions while its price fell 2.0%. With every distribution reinvested, the fund returned −0.1%. At its price on Nov 4, 2026 the latest distribution annualizes to 7.2%, paid periodically.
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, KIQQ against PCOV, data as of Nov 4, 2026. https://etfiq.com/compare/income/kiqq-vs-pcov
ETFIQ. (Nov 4, 2026). KIQQ against PCOV. Retrieved from https://etfiq.com/compare/income/kiqq-vs-pcov
[KIQQ against PCOV (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/kiqq-vs-pcov)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.